Skip to main content

Movantik FDA Approval History

FDA Approved: Yes (First approved September 16, 2014)
Brand name: Movantik
Generic name: naloxegol
Dosage form: Tablets
Company: AstraZeneca
Treatment for: Constipation

Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.

Development timeline for Movantik

DateArticle
Sep 16, 2014Approval FDA Approves Movantik (naloxegol) for Opioid-Induced Constipation
Jun 11, 2014FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists
Nov 19, 2013New Drug Application for Naloxegol Accepted by United States Food and Drug Administration
Feb 26, 2013AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

See also

Movantik (naloxegol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer